BESREMi (ropeginterferon alfa-2b) represents a breakthrough in treating polycythemia vera (PV)—a rare blood disorder where the body overproduces red blood cells, creating significant health risks. Commercially available since 2021, this innovative long-acting pegylated interferon alfa-2b addresses a fundamental patient need: fewer injections without compromising treatment quality. This...